ESTEVE’S R&D, AGAIN RATED ’EXCELLENT’ BY PROFARMA PLAN
The Profarma Plan (Plan to Promote Scientific Research, Technological Development and Innovation in the Pharmaceutical Industry) of the Ministry of Industry, Energy and Tourism has one more year rated ESTEVE's R&D activities as 'excellent'. This is the 29th consecutive time that our laboratory receives this seal of quality, ever since the launch of Profarma in 1986.
ESTEVE is classified in Group A of the Proforma Plan (2013-2016), which includes pharmaceutical companies with significant research activities that have their own production center or basic or preclinical R&D.
Innovation and internationalization are two strategic axes at ESTEVE, a company that invests 63 million Euros a year in research and has a workforce of 2,279 professionals, 10% of which devoted exclusively to R&D activities. This firm commitment and effort have again resulted in the annual renovation of the maximum rating granted by Profarma, an official seal of quality that fosters R&D in the pharmaceutical sector.
You can follow ESTEVE on Twitter at this link: twitter.com/esteve_news.
ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY
Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spainread more
NURSES OFFER CARE AND PREVENTION OF DRY EYE, A CONDITION THAT AFFECTS 60% OF PEOPLE OLDER THAN 45 YEARS
Dry eye care and prevention is a pending issue in the Spanish society and a source of great concern for specific patients, such as those admitted to Intensive Care Units.read more
The longer time...
ONE THIRD OF DIABETIC PATIENTS ARE OLDER THAN 75 YEARS AND THEIR HYPOGLYCEMIA GOES UNDETECTED IN 1 OUT OF 5 CASES
According to experts attending Diabeclass, a meeting organized by ESTEVEread more
at its corporate headquarters titled "Managing elderly patients with
type 2 diabetes".
The priority ...